Abstract Number: 2622 • ACR/ARP Annual Meeting 2019
A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis
Background/Purpose: Rituximab therapy for ANCA-associated vasculitis (AAV) patients was covered by insurance from 2013 in Japan. Administration of four once-weekly doses of 375 mg/m2 rituximab…
ACR Meeting Abstracts